In 2024, the FDA approved amivantamab for multiple indications in NSCLC: in combination with carboplatin and pemetrexed for EGFR exon 19 deletions or exon 21 L858R substitution mutations post-EGFR TKI treatment (September); with lazertinib as a first-line treatment for EGFR exon 19 deletions or exon 21 L858R mutations (August); and with carboplatin and pemetrexed as a first-line treatment for EGFR exon 20 insertion mutations (March) [2–4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.